🔎 Trials Near Me

Akèy › Leksemi mieloïd egi › Florid › Miami

Etid klinik pou Leksemi mieloïd egi nan Miami, FL

24 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote Miami (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Ap rekriteFaz 2
  • Miami Cancer Institute, Miami
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Ap rekriteFaz 2
  • Miami Cancer Institute, Miami
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Ap rekriteFaz 2
  • Miami Cancer Institute, Miami
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Ap rekriteFaz 2
  • Miami Cancer Institute, Miami
Laj 18 a 59 · Tout sèks · Mizajou Sep 22, 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Ap rekriteFaz 3
  • University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
6 Months – 21 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT04293562

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

Ap rekriteFaz 2
  • University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT06504459

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Ap rekriteFaz 3
  • University of Miami, Miami
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07007312

eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation

Ap rekrite
  • University of Miami, Miami
Laj 18 ak plis · Tout sèks · Mizajou Aug 13, 2026 · NCT07469592

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Ap rekriteFaz 2/3
  • Bioresearch Partners, Miami
Laj 18 a 80 · Tout sèks · Mizajou Aug 5, 2026 · NCT06788756

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

Ap rekriteFaz 2
  • University of Miami, Miami
Laj 18 ak plis · Tout sèks · Mizajou Jul 10, 2026 · NCT05442216

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Ap rekriteEtid obsèvasyon
  • University of Miami (peds), Miami
  • Niklaus Children's Hospital, Miami
Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Ap rekriteFaz 2/3
  • University of Miami - Sylvester Comprehensive Cancer Center, Miami
Laj 18 ak plis · Tout sèks · Mizajou Apr 30, 2026 · NCT04256317

Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

Ap rekriteFaz 2
  • University of Miami, Miami
Laj 18 a 75 · Tout sèks · Mizajou Apr 16, 2026 · NCT06782542

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Ap rekriteFaz 1/2
  • University of Miami, Miami
  • Miami Cancer Institute, Miami
Laj 12 ak plis · Tout sèks · Mizajou Mar 24, 2026 · NCT04988555

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Ap rekriteFaz 1
  • University of Miami Health System, Miami
Laj 18 ak plis · Tout sèks · Mizajou Jan 16, 2026 · NCT05143996

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Ap rekriteFaz 1
  • University of Miami, Miami
Laj 18 ak plis · Tout sèks · Mizajou Jan 8, 2026 · NCT05597306

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

Ap rekriteFaz 1
  • Sylvester Comprehensive Cancer Center, Miami
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2025 · NCT06501196

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Ap rekriteFaz 1/2
  • University of Miami - Miller School of Medicine, Miami
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2025 · NCT03850574

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Ap rekriteVolontè an sante akeyi
  • University of Miami, Miami
Laj 18 a 120 · Tout sèks · Mizajou Jul 25, 2025 · NCT05237258

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

Ap rekriteFaz 1
  • University of Miami, Miami
Laj 18 ak plis · Tout sèks · Mizajou May 11, 2025 · NCT06634394

Etid Leksemi mieloïd egi nan lòt vil

Lòt etid nan Miami

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.